New hope for transplant patients: drug combo may tame deadly immune attack
NCT ID NCT06936566
First seen Mar 29, 2026 · Last updated May 08, 2026 · Updated 4 times
Summary
This study tests a drug called ruxolitinib for treating acute graft-versus-host disease (GVHD), a serious condition where donor cells attack the patient's body after a bone marrow transplant. About 98 adults with moderate to severe GVHD will receive either ruxolitinib alone or with steroids, depending on their risk level. The goal is to see if ruxolitinib can control GVHD better than standard steroid treatment, with fewer side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE EFFECTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fred Hutchinson Cancer Research Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Kansas University Medical Center
RECRUITINGFairway, Kansas, 66205, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Moffitt Cancer Center
NOT_YET_RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ohio State University
NOT_YET_RECRUITINGColumbus, Ohio, 43210, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pennsylvania
NOT_YET_RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-••••
Contact
-
Vanderbilt University
RECRUITINGNashville, Tennessee, 37235, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University
NOT_YET_RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Winship Cancer Institute, Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.